Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus ANSPOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus ANSPOR.
ANCEF vs ANSPOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic